Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Genespire appoints Karen Aiach-Pignet as Chief Executive Officer
PRESS RELEASE Genespire appoints Karen Aiach-Pignet as Chief Executive Officer Karen's appointment bolsters Genespire's position as a leader in in-vivo lentiviral gene therapy Milan, Italy, 12 September 2024– Genespire, a biotechnology company developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases, today announces the appointment of Karen Aiach-Pignet as Chief Executive Officer following Dr. Julia Berretta, the former CEO, stepping down...
Nasdaq GlobeNewswire
12/09/2024
BIOVAXYS ANNOUNCES CLOSING OF THIRD TRANCHE OF PRIVATE PLACEMENT
Each Unit consists of one common share in the capital of the Company (each, a "Share") and one whole common share purchase warrant (each, a "Warrant"), whereby each Warrant is convertible into one additional Share at an exercise price of $0.15 until September 11, 2026, being the date that is 24 months from the date of issue. Each Unit consists of one common share in the capital of the Company (each, a " Share ") and one whole common share purchase warrant (each, a…
PR Newswire
12/09/2024
Nontuberculous Mycobacterial Infection Market to Exhibit Growth at a CAGR of…
Key Takeaways from the Nontuberculous Mycobacterial Infection Market Report Key Takeaways from the Nontuberculous Mycobacterial Infection Market Report Discover which therapies are expected to grab the major nontuberculous mycobacterial infection market share @Nontuberculous Mycobacterial Infection Market Report Nontuberculous Mycobacterial Infection Overview Nontuberculous mycobacteria (NTM) infections are diseases caused by bacteria from the Mycobacterium genus, excluding...
PR Newswire
11/09/2024
Teva to Present at the Bank of America 2024 Global Healthcare Conference
To access a live webcast of the presentation, visit Teva's Investor Relations website athttps://ir.tevapharm.com/Events-and-Presentations.An archived version of the webcast will be available within 24 hours after the end of the live discussion. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global pharmaceutical leader with a category-defying portfolio, harnessing our generics expertise and stepping up innovation to continue the momentum behind the...
Nasdaq GlobeNewswire
11/09/2024
Annual Report 2023/24 - Strengthened commercial focus after challenging year
ANNOUNCEMENT NO. 273 11 September 2024Annual Report 2023/24 (1 July 2023 - 30 June 2024) Strengthened commercial focus after challenging year ChemoMetec's revenue fell by 8% in 2023/24 to DKK 407.4 million, and operating profit (EBITDA) was down by 26% to DKK 186.2 million. Revenue was adversely affected by a 35% decline in sales of instruments, while sales of consumables and services were up by 13% in total. During the year, ChemoMetec initiated a gradual launch of the XcytoMatic...
Nasdaq GlobeNewswire
11/09/2024
Guidance for the 2024/25 financial year
ANNOUNCEMENT NO. 272 11 September 2024 Guidance for the 2024/25 financial yearChemoMetec has today approved the annual report for 2023/24, including the guidance for 2024/25, which is considered inside information.For 2024/25, ChemoMetec expects revenue in the range of DKK 435-450 million (2023/24: DKK 407.4 million) and EBITDA in the range of DKK 216-223 (2023/24: DKK 186.2 million).The annual report for 2023/24, which is released along with this announcement, sets out the...
Nasdaq GlobeNewswire
11/09/2024
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of…
BOSTON and LONDON, Sept.11, 2024(GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that it has commenced an underwritten public offering of $150 million of American Depositary Shares (“ADSs”), each representing one ordinary share. All of the ADSs are being offered by Centessa. In addition, Centessa intends to grant the underwriters a...
Nasdaq GlobeNewswire
11/09/2024
Global Health Exhibition Announces Opportunity for Healthcare Startups to secure…
Closely aligned with the Kingdom of Saudi Arabia's healthcare objectives including crisis response and health security, technological and digital transformation, public health and disease prevention and health innovation, Vision NextGen judges anticipate high demand to join a shortlist of 30 companies from an anticipated longlist of over 150 businesses. Six finalists drawn from the shortlist will present to the competition's expert judging panel live at the Exhibition on 23 October 2024. The…
PR Newswire
11/09/2024
Ultimovacs Announces Patient Recruitment Discontinuation in LUNGVAC Trial…
Oslo, September 11, 2024:Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announced that the company has agreed with the investigators conducting the LUNGVAC trial (NCT05344209) to discontinue patient recruitment. LUNGVAC is an investigator-initiated, randomized Phase II trial designed to assess the impact of UV1 in combination with the checkpoint inhibitor cemiplimab or pembrolizumab as first-line...
Nasdaq GlobeNewswire
11/09/2024
Cell-Based Assays Market to Grow from USD 17.3B in 2024 to USD 24.3B by 2029 at…
Browse in-depth TOC on "Cell-Based Assays Market" Browse in-depth TOC on "Cell-Based Assays Market" 200 - Tables50 - Figures350 - Pages Market Segmentation by Offering The global cell-based assays market is categorized into consumables, instruments, software, and services. Among these, the services segment is projected to experience the highest CAGR during the forecast period. Increasingly, researchers and pharmaceutical companies are outsourcing aspects of their...
PR Newswire
11/09/2024
KFSHRC Announced a Strategic Partner for 2024 NYC C3 Summit Davos of Healthcare
RIYADH, Saudi Arabia, Sept.11, 2024(GLOBE NEWSWIRE) -- In a significant move to bolster its global presence, the King Faisal Specialist Hospital & Research Centre (KFSHRC) is set to join as a key partner in the 2024 NYC C3 Summit Davos of Healthcare, kicking off on Monday in New York City. Under the theme "Tech-Driven Healthcare Evolution & Breakthroughs: Addressing Future Global Challenges & Impact of Advanced Technologies," the summit will foster dialogue and...
Nasdaq GlobeNewswire
11/09/2024
RenovaroCube Announces Strategic Offering of Up to 20% Ownership
This opportunity will be available to all potential investors including current shareholders of RENB.Cube is a molecular data science company with a background in FinTech and a 10-year history. It brings together proprietary artificial intelligence (AI) technology for multi-omics and multi-modal data analysis, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes, beginning with cancer.“Newly raised...
Nasdaq GlobeNewswire
11/09/2024
Tinnitus Quest Launches to Find a Cure for Hearing Disorder Affecting Millions
Despite the prevalence and profound impact of tinnitus, no cure or effective treatment is available. Many sufferers are simply advised to "learn to live with it." "Tinnitus Quest believes this status quo is unacceptable," said Sven Köllmann, founder of Tinnitus Quest. "We are committed to changing the narrative by funding agile research, investigating new research questions that have not been asked before, aimed at silencing tinnitus once and for all." Despite the…
PR Newswire
11/09/2024
FLOWPHYSIX ANNOUNCES STRATEGIC PARTNERSHIP WITH 3COMMA FOR INTERNATIONAL…
3comma Managing Partner and former Vice President of International at Penumbra, Inc., Marc Paris believes the FLOWRUNNER System will make an immediate impact in the peripheral thrombectomy segment. "We can rapidly activate our established international commercial infrastructure to accelerate adoption of the FLOWRUNNER system. We are confident that FlowPhysix will be the next major disruptor in the global thrombectomy market and we are excited to be part of this endeavor," Paris said…
PR Newswire
11/09/2024
IM Cannabis Announces Appointment of Shmulik Arbel to Board of Directors
Mr. Arbel retired as Deputy CEO from Leumi, Israel's largest banking group, in April 2023, where he was instrumental in business growth and leading the service revolution. With over 25 years of experience at Leumi, Arbel has held senior roles throughout the organization, such as head of retail banking, head of the corporate division, and as chairman of Leumi UK. With key roles in Israel, New York and London, Mr. Arbel has a wide view on international business. Mr. Arbel retired as Deputy CEO...
PR Newswire
11/09/2024
Trading by management and close relations of management
Please read the full announcement in PDFAttachment 2024_35_Trading_By_Management
Nasdaq GlobeNewswire
11/09/2024
IGI Announces Publication in Nature Cancer on ISB 2001, IGI's Innovative…
Article highlights preclinical findings demonstrating ISB 2001 can potentially overcome myeloma cell escape mechanisms to evade therapeutic anti-tumor activity Data show superior killing potency of multiple myeloma tumor cells by ISB 2001 when compared to several approved bispecific therapies and combination of therapiesNEW YORK, Sept.11, 2024(GLOBE NEWSWIRE) -- Ichnos Glenmark Innovation (IGI), an alliance between Ichnos Sciences Inc., a global fully-integrated clinical-stage...
Nasdaq GlobeNewswire
11/09/2024
TCI Revolutionizes Weight Management with Breakthrough GLP-1 Innovation
The Science Behind TCI's GLP-1 Formula The Science Behind TCI's GLP-1 Formula TCI leverages its proprietary Bio-Resource Data Mining technology, an AI-powered system that autonomously identifies potent natural compounds. Backed by in-vitro studies and human trials, TCI's GLP-1 formula has proven to be a game-changer in the health and wellness sector. The formula stimulates natural GLP-1 secretion, enhances fat metabolism, stabilizes blood glucose, and induces white fat browning—making it an...
PR Newswire
11/09/2024
Nomination Committee of AB SKF for the Annual General Meeting 2025
Marcus Wallenberg, FAM Philip Ahlgren, Cevian CapitalAnders Algotsson, AFA FörsäkringAnders Jonsson, Skandia, andHans Stråberg, Chair of the Board Marcus Wallenberg, FAM Philip Ahlgren, Cevian Capital Anders Algotsson, AFA FörsäkringAnders Jonsson, Skandia, and Hans Stråberg, Chair of the Board The Annual General Meeting of AB SKF will be held inGothenburgon Tuesday,1 April 2025. Shareholders who wish to submit proposals to the Nomination Committee, may contact the Chair of...
PR Newswire
11/09/2024
Inside information: Orion upgrades full-year outlook for 2024
ORION CORPORATIONSTOCK EXCHANGE RELEASE – INSIDE INFORMATION 11 SEPTEMBER 2024 at 09:30 EEST Inside information: Orion upgrades full-year outlook for 2024Orion Corporation upgrades the full-year outlook for 2024 both for the part regarding net sales and operating profit. Orion's product sales and royalty income has continued to grow faster than expected during the second half of 2024 and this good development is anticipated to continue during the remainder of the year...
Nasdaq GlobeNewswire
11/09/2024
EQT Life Sciences leads EUR 93 million oversubscribed Series A round in PanTera…
Targeted Alpha Therapy is a promising new cancer treatment approach that enables safe and effective delivery of radiation to the cancer cells by radioisotopes that emit highly energetic alpha particles. The radiation effect of the alpha particle is more localized compared to other approaches and as such can destroy the cancer cells to which it is attached without harming surrounding healthy tissue. The most promising alpha emitter for this approach is 225Ac. As a result, demand for 225Ac is…
PR Newswire
11/09/2024
Press Release: Dupixent phase 3 study confirms significant improvements in itch…
Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU Confirming the results of CUPID-A, this second pivotal study in biologic-naïve patients met primary and key secondary endpoints, showing treatment with Dupixent resulted in a nearly 50% reduction in itch and urticaria activity scores compared to placeboMore than 300,000 people in the US suffer from chronic spontaneous urticaria (CSU) that is inadequately controlled by antihistaminesData...
Nasdaq GlobeNewswire
11/09/2024
IBA's joint venture PanTera secures EUR 93 million in oversubscribed Series A…
Louvain-la-Neuve, Belgium, September 11, 2024 – IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, is pleased to share the below press release from its joint venture PanTera, which is focussed on the production of actinium-225, a novel radioisotope used in a new class of targeted treatments for cancer. The Series A financing values PanTera at about EUR 280 million post money. Prior to the funding round, IBA had a 47.8% shareholding in PanTera and...
Nasdaq GlobeNewswire
11/09/2024
Press Release: Dupixent is the first and only biologic to achieve significant…
Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal studyStudy met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placeboDupixent is the first medicine to show significant steroid-sparing effect in this debilitating and life-threatening disease If approved, Dupixent...
Nasdaq GlobeNewswire
11/09/2024
Altri Comunicati